伴随NIH经费削减而来的是患者安全与科学数据的风险
Along with NIH cuts come risks to patient safety and scientific data
生命科学资讯
生物技术与制药领域的最新动态
制药业生产繁荣的四大启示
4 takeaways from pharma’s manufacturing boom
礼来公司成为首家市值突破万亿美元的制药企业
Eli Lilly becomes first drugmaker to hit $1 trillion in market value
#Eli Lilly#drugmaking peers#pharmaceutical company#success developing#developing medicines
眼疾治疗管线下一步进展如何？
What’s next in the eye disease pipeline?
#disease pipeline#eye disease#pipeline#spurred investments#maintain momentum
制药业将于2026年迎来酝酿多年的关键“转折点”
Pharma faces a critical ‘turning point’ in 2026, years in the making
#turning point’#health landscape#pricing deals#Pharma faces#pharma shape
大型制药公司员工如何评价他们的CEO？
How do Big Pharma employees rate their CEOs?
#Big Pharma#employees rate#Big#pharma company#Pharma employees
随着Madrigal面临MASH竞争对手，留住患者与寻找新患者同等重要。
As Madrigal faces MASH rivals, keeping patients is as critical as finding new ones
#MASH rivals#faces MASH#drug Rezdiffra#exceeded expectations#Madrigal faces
Amylin有望在下一波减肥药浪潮中称雄。
Amylin could reign supreme in the next wave of obesity drugs
#weight management#critical readouts#reign supreme#obesity drugs#key candidates
制定癌症恶病质治疗路径
Developing a path forward in cancer cachexia
#Pfizer scientists#cachexia Pfizer#path forward#advance understanding#potential treatments
阿尔茨海默病研发新突破即将到来，但非近在咫尺
The next leap in Alzheimer’s R&D is coming, but not around the corner
#couple drugs#true paradigm#paradigm shift#Alzheimer#coming
这位医药网红是人类还是AI？
Is that pharma influencer human or AI?
#influencer human#pharma influencer#pharma marketing#pharma#influencer
FDA发布定制药物疗法新监管路线图
FDA unveils new regulatory roadmap for bespoke drug therapies
#Vinay Prasad#Martin Makary#FDA unveils#plausible mechanism#regulatory roadmap